Provided by Tiger Fintech (Singapore) Pte. Ltd.

Indaptus Therapeutics, Inc.

0.8051
-0.0017-0.21%
Post-market: 0.81990.0148+1.84%18:18 EDT
Volume:6.60K
Turnover:5.33K
Market Cap:11.37M
PE:-0.47
High:0.8180
Open:0.8176
Low:0.7800
Close:0.8068
Loading ...

Company Profile

Company Name:
Indaptus Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
7
Office Location:
Three Columbus Circle,15th Floor,New York,New York,United States
Zip Code:
10019
Fax:
- -
Introduction:
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Directors

Name
Position
Jeffrey A. Meckler
Chief Executive Officer, Vice Chairman of the Board of Director
John W. Kozarich
Chairman of the Board of Director
Anthony J. Maddaluna
Director
Gil Bianco
Director
Hila Karah
Director
Issac Silberman
Director
Roger J. Pomerantz
Director
William B. Hayes
Director

Shareholders

Name
Position
Jeffrey A. Meckler
Chief Executive Officer, Vice Chairman of the Board of Director
Nadav Navon
Chief Operating Officer
Nir Sassi
Chief Financial Officer
R. Michael Gendreau
Chief Medical Officer
Walt A. Linscott
Chief Business Officer